Manus, the proven bioalternatives scale-up platform, today announced the launch of the MAD7™ licensing program, expanding access to a powerful, flexible, and cost-effective CRISPR nuclease designed to accelerate R&D across applications.

‍

Originally developed by Inscripta, MAD7 is a high-performance CRISPR enzyme offering strong on-target activity and reduced off-target edits, with a unique TTTN PAM motif that enables targeting of genomic sites not accessible with SpCas9. MAD7 supports a broad set of use cases, across microbial, mammalian, and plant cells, to address opportunities in agricultural biotechnology, specialized crops varieties, microbial engineering for human health, therapeutics, small-molecules, and food-ingredient production.

‍

“In a field where access to genome-editing tools is often constrained by complex and expensive licensing, MAD7 stands out as an open, practical alternative,” says Rob Evans, Head of Business Development, Manus. “By combining a best-in-class CRISPR nuclease with a flexible licensing model, we’re making it easier for innovators to move from concept to impact.”

‍

MAD7 is available under a tailored license framework, with terms designed to match project scale and needs, avoiding restrictive terms and high fees often associated with other proprietary nucleases.

‍

Following the April 2025 merger of Inscripta and Manus, MAD7 now sits within Manus’ broader industrial biomanufacturing platform. While Manus advances its integrated, end-to-end scale-up capabilities for bioalternative products, the MAD7 licensing program will continue as an independent, standalone service – fully supported by Manus, and accessible to researchers and partners worldwide.

‍

“MAD7 lets teams innovate with flexibility and confidence,” Evans adds. “It fits naturally with our ambition as The BioAlternatives Company: to turn breakthrough biotechnology into real-world impact.”

‍

Researchers and partners interested in MAD7 licensing can learn more at www.madzymes.com.

‍